The Bridge Project

Imaging system helps surgeons remove tiny ovarian tumors: More effective surgery could boost survival rates for ovarian cancer.  <a href="http://news.mit.edu/2019/imaging-system-surgeons-remove-ovarian-tumors-0424" target="_blank"><strong>Read more.</strong></a></span>
Technique identifies T cells primed for certain allergies or infections: Researchers develop a method to isolate and sequence the RNA of T cells that react to a specific target. <a href="http://news.mit.edu/2019/t-cells-target-allergies-infections-1119" target="_blank"><strong>Read more.</strong></a></span>
Measuring chromosome imbalance could clarify cancer prognosis: A study of prostate cancer finds “aneuploid” tumors are more likely to be lethal than tumors with normal chromosome numbers. <a href="http://news.mit.edu/2019/aneuploidy-chromosome-imbalance-cancer-0513"target="_blank"><strong>Read more.</strong></a>
New optical imaging system could be deployed to find tiny tumors: Near-infrared technology pinpoints fluorescent probes deep within living tissue; may be used to detect cancer earlier. <a href="http://news.mit.edu/2019/near-infrared-optical-imaging-system-small-tumors-0307" target="_blank"><strong>Read more.</strong></a></span>
Biologists’ new peptide could fight many cancers: Drug that targets a key cancer protein could combat leukemia and other types of cancer. <a href="http://news.mit.edu/2018/peptide-could-fight-many-cancers-0115"target="_blank"><strong>Read more.</strong></a>
Over the river and do some good. The Bridge Project collaboration accelerates new, highly original, and powerful approaches to defeating cancer. <a href="http://news.mit.edu/2017/mit-koch-institute-dana-farber-harvard-bridge-project-cancer-research-1122"target="_blank"><strong>Read more.</strong></a>
Honey, I Shrunk the Spheroids: To explore the relationship between tumor size and the efficacy of continuous low-dose chemotherapy, Cima Lab researchers grew spherical ovarian cancer cell clusters 100 or 200 microns in diameter and exposed them to different doses of cisplatin. <a href="https://news.mit.edu/2017/guidance-targeting-residual-ovarian-tumors-0523"target="_blank"><strong>Read more.</strong></a>